Balyasny Asset Management’s Fresenius Medical Care FMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-75,530
Closed -$1.8M 3096
2025
Q4
$1.8M Buy
+75,530
New +$1.88M ﹤0.01% 1914
2024
Q3
Sell
-57,433
Closed -$1.1M 2876
2024
Q2
$1.1M Buy
+57,433
New +$1.17M ﹤0.01% 1755
2023
Q4
Sell
-91,982
Closed -$1.98M 2613
2023
Q3
$1.98M Sell
91,982
-554,163
-86% -$13.5M ﹤0.01% 1375
2023
Q2
$15.5M Sell
646,145
-104,465
-14% -$2.4M 0.03% 618
2023
Q1
$16M Buy
750,610
+307,801
+70% +$5.89M 0.04% 598
2022
Q4
$7.24M Buy
442,809
+285,552
+182% +$4.23M 0.02% 867
2022
Q3
$2.21M Buy
+157,257
New +$2.97M 0.01% 1440
2021
Q2
Sell
-7,574
Closed -$279K 2083
2021
Q1
$279K Buy
+7,574
New +$286K ﹤0.01% 1519
2020
Q4
Sell
-20,008
Closed -$850K 1449
2020
Q3
$850K Buy
+20,008
New +$863K 0.01% 1030
2020
Q2
Sell
-49,434
Closed -$1.62M 1250
2020
Q1
$1.62M Buy
+49,434
New +$1.84M 0.02% 657
2018
Q2
Sell
-27,341
Closed -$1.4M 1886
2018
Q1
$1.4M Buy
+27,341
New +$1.46M 0.01% 1102

Other funds holding FMS

Balyasny Asset Management's FMS Position: Q1 2026 in Review

Balyasny Asset Management sold out of Fresenius Medical Care (FMS) in Q1 2026, closing a stake of 75,530 shares — an estimated $1.8M sold.

Balyasny Asset Management first reported a position in FMS in Q1 2018 and held it in 11 quarters. The position peaked at $16M in Q1 2023. 218 funds tracked by Wall St. Rank hold FMS as of Q1 2026.

  • Balyasny Asset Management reported no remaining Fresenius Medical Care position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 75,530 Fresenius Medical Care shares in Q1 2026, an estimated $1.8M.
  • Balyasny Asset Management first reported a position in Fresenius Medical Care in Q1 2018 and held it in 11 quarters.
  • Balyasny Asset Management's Fresenius Medical Care position peaked at $16M in Q1 2023.
  • 218 funds tracked by Wall St. Rank held Fresenius Medical Care as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.